Skip to content

Omeros OMER Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Immunome logo
ImmunomeIMNM
-$79K
Vor Biopharma logo
Vor BiopharmaVOR
$0+100%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$30M
Opko Health logo
Opko HealthOPK
$34K-99.1%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal.

The official record: Omeros’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's gain/loss on asset sales?
Omeros (OMER) reported gain/loss on asset sales of $59.4M in Q4 2025.
What is the long-term trend for Omeros's gain/loss on asset sales?
Over 4 years (2021 to 2025), Omeros's gain/loss on asset sales has grown at a -6.5% compound annual growth rate (CAGR), from $310.56M to $237.59M.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.